Harokopio University
Nutritional interventions in inflammatory diseases: investigating the molecular pathways
Abstract
dc:descriptionInflammation is a biological process against harmful stimuli, such as pathogens, damaged cells and toxic compounds which contributes in infection control and tissue repairing. Inflammatory dysregulation and chronic inflammatory responses may lead to various chronic inflammatory conditions, such as Non-alcoholic fatty liver disease (NAFLD) and Inflammatory Bowel Diseases (IBD). NAFLD is the most common liver disease, characterised by excessive fat accumulation in liver, not caused by alcohol consumption. IBD represents a group of intestinal disorders that are characterized by chronic inflammation of the digestive tract. Both conditions show a high prevalence in Western societies, mainly due to the westernised lifestyle, and are in need for new promising options for treatment with the least side effects. Also, they share common pathogenic features, such as increased intestinal permeability, gut dysbiosis and chronic inflammatory responseMastiha, is a plant product with a plethora of bioactive constituents, such as terpenic acids, phenolic compounds and phytosterols. Mastiha’s anti-inflammatory properties are well established. The aim of this dissertation was to investigate the molecular pathways under which Mastiha exhibits its anti-inflammatory action. More specifically, we explored the effectiveness of Mastiha as a non-pharmacological intervention in both NAFLD and IBD, and which molecular mechanisms accompany this effect.In order to evaluate the effect of Mastiha in NAFLD we designed a multicenter, randomized, double-blinded and placebo-controlled clinical trial and investigated the effect on liver inflammation and fibrosis through MRI, biochemical, inflammatory and multi-omic analyses. After six months of Mastiha supplementation, we observed a significant improvement on microbiota dysbiosis as depicted in Bray-Curtis dissimilarity index which was significantly greater among patients that received Mastiha, compared to Placebo. Also, Mastiha decreased the proportion of Flavonifractor, a taxa involved in the catabolism of quercetin, a flavonoid with antioxidant and anti-inflammatory properties. The above effects paralleled with a decrease in plasma cholic acid and phospholipids, possibly attributed to the bioavailable triterpenic acids of Mastiha. Finally, in severely obese patients we observed an improvement of the liver fibrosis as assessed via MRI. In IBD, we applied a randomized, double-blind, placebo-controlled, parallel-group clinical trial with a 3 months duration for patients in relapse and a 6 months duration in patients for remission. Quantification of inflammatory biomarkers revealed a significant increase of serum interleukin-17A (IL-17A) in the Mastiha group and the different mean changes between Mastiha and placebo groups in inactive patients, with this pattern being observed specifically in Crohn’s disease (CD) patients in remission. Similarly, metabolomics analysis revealed an increase in metabolites, such as the aromatic aminoacids phenylalanine, tyrosine and tryptophan together with alanine, glycine and acetic acid, only in patients in remission. As tryptophan is involved in T-helper-17 regulation, the above suggest a possible shift of Th-17 cells to a more protective pathway in quiescent IBD. Finally, Mastiha regulated some gut microbiota related to inflammatory processes, although no evident effect was observed on microbiota dysbiosis.Taking into account that all the above pointed towards Mastiha’s anti-inflammatory activity, we examined whether this action is attributed to epigenetic mechanisms related to inflammation, such as regulation of miRNA levels. MicroRNAs are small molecules that serve as important regulators of gene expression, including inflammatory pathways. Interestingly, the same microRNA, miR-155 (implicated in lipid and Th-17 regulation) was modified by Mastiha in both clinical trials, revealing a possible common mechanism across Mastiha supplementation in two different inflammatory conditions. More studies are needed to further explore this mode of action and introduce other potential pathways that explain Mastiha’s valuable anti-inflammatory action.
Degree
thesis:*- Grantor dc:publisher
- Harokopio University
- Year dc:date
- 2021
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Amerikanou, Charalampia
- Αμερικάνου, Χαραλαμπία
Subjects
dc:subject × 23- Μαστίχα Χίου
- Μη αλκοολική λιπώδης νόσος του ήπατος
- Ιδιοπαθείς φλεγμονώδεις νόσοι εντέρου
- Εντερικό μικροβίωμα
- Κλινική δοκιμή
- Chios Mastiha
- Non alcoholic fatty liver disease
- Inflammatory bowel diseases (IBD)
- Gut microbiome
- Clinical trial
- MicroRNAs
- Βιολογία
- Φυσικές Επιστήμες
- Βιοχημεία και Μοριακή βιολογία
- Επιστήμες Υγείας
- Ιατρική και Επιστήμες Υγείας
- Διατροφή και Διαιτολογία
- Biological Sciences
- Natural Sciences
- Biochemistry and Molecular Biology
- Health Sciences
- Medical and Health Sciences
- Nutrition and Dietetics
Rights
dc:rights- Statement dc:rights
-
- BY_NC_ND_4_0
- Language dc:language
- eng
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/49555